Analyst’s Ratings on ZIOPHARM Oncology Inc (ZIOP)

Analysts are weighing in on how ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) , might perform in the near term. Wall Street analysts have a  assessment of the stock, with a mean rating of 3.0. The stock is rated as buy by 0 analysts, with 1 outperform and 3 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.

For the current quarter, the 6.00 analysts offering adjusted EPS forecast have a consensus estimate of $-0.11 a share, which would compare with $-0.11 in the same quarter last year. They have a high estimate of $-0.09 and a low estimate of $-0.12. Revenue for the period is expected to total nearly $1.76M from $272.00K the year-ago period.

For the full year, 6.00 Wall Street analysts forecast this company would deliver earnings of -0.43 per share, with a high estimate of $-0.38 and a low estimate of $-0.45. It had reported earnings per share of $-0.37 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $7.07M versus 4.33M in the preceding year.

Among the 2 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for ZIOP is $14.00 but some analysts are projecting the price to go as high as $21.00. If the optimistic analysts are correct, that represents a 212 percent upside potential from the recent closing price of $6.73. Some sell-side analysts, particularly the bearish ones, have called for $7.00 price targets on shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) .

In the last reported results, the company reported earnings of $-0.11 per share, while analysts were calling for share earnings of $-0.25. It was an earnings surprise of 56.00%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexons synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 that is used with the oral activator veledimex and evaluated for the treatment of metastatic melanoma and unresectable recurrent or metastatic breast cancer. The synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells and T cell receptors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.